ArticleMolecular immunology2012
Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.
Article in Molecular immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review).International journal of molecular medicine · 2026Review
- Exploring the theranostic potentials of miRNA and epigenetic networks in autoimmune diseases: A comprehensive review.Immunity, inflammation and disease · 2023Review
- Cytokines and microRNAs in SARS-CoV-2: What do we know?Molecular therapy. Nucleic acids · 2022Review
- Altered expression of microRNAs and B lymphocytes during Natalizumab therapy in multiple sclerosis.Heliyon · 2021Review
- Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis.Frontiers in neurology · 2021Review
- Immunological Involvement of MicroRNAs in the Key Events of Systemic Lupus Erythematosus.Frontiers in immunology · 2021Review
- The Pathogenic Role of Dysregulated Epigenetic Modifications in Autoimmune Diseases.Frontiers in immunology · 2019Review
- Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity.Cellular & molecular immunology · 2018Review
- The Involvement of MicroRNAs in Modulation of Innate and Adaptive Immunity in Systemic Lupus Erythematosus and Lupus Nephritis.Journal of immunology research · 2018Review
- Genome-Wide Association Analysis of Age-Dependent Egg Weights in Chickens.Frontiers in genetics · 2018Article
- Genome-wide association study reveals putative role of gga-miR-15a in controlling feed conversion ratio in layer chickens.BMC genomics · 2017Article
- Epigenetic Control of B Cell Development and B-Cell-Related Immune Disorders.Clinical reviews in allergy & immunology · 2016Review
- The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation.International journal of molecular sciences · 2015Review
- Biomarkers for kidney involvement in pediatric lupus.Biomarkers in medicine · 2015Review
- The pathogenesis, diagnosis and treatment of lupus nephritis.Current opinion in rheumatology · 2014Review
- MicroRNA Regulation in Systemic Lupus Erythematosus Pathogenesis.Immune network · 2014Review
- MicroRNAs in autoimmune diseases.BioMed research international · 2014Review
- Progress and challenge of microRNA research in immunity.Frontiers in genetics · 2014Review
- MicroRNAs, Major Players in B Cells Homeostasis and Function.Frontiers in immunology · 2014Review
- IFNα Inducible Models of Murine SLE.Frontiers in immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
MicroRNAs (miRNAs) are involved in the regulation of immunity via targeting of mRNA encoding immune response elements. In this report, alterations in the expression of microRNAs as autoantibody levels increase was investigated. The (NZB×NZW)F1 or B/W mouse model of systemic lupus erythematosus (SLE) naturally has increased autoantibodies with aging. IFNα (type I IFN) accelerates B/W disease, however, the effects of a related IFN, IFNλ, which is a type III IFN, is largely unknown. The purpose of the study was to investigate the relationship between IFN-accelerated disease, microRNAs, immunoregulatory B cell subsets and autoantibody production in the autoimmune-prone environment in vivo. B/W mice received osmotic pumps to chronically deliver IFNα and IFNλ for up to 16 weeks. Urine protein level was monitored weekly by urine strips and proteinuria was used as the disease marker. Splenic cells were taken for flow analysis of B cell subsets and levels of microRNAs determined. Plasma were analyzed for autoantibodies and microRNA levels. As a result of treatment, IFNα accelerated proteinuria in a dose dependent manner, while IFNλ single treatment did not show a significant effect, but greatly enhanced low dose IFNα effects in the combination treatment. Both the splenic cellular and plasma miR-15a were elevated in diseased compared to pre-diseased mice as well as autoantibody levels. Autoantibodies and miR-15a levels were significantly correlated. The immunosuppressive B subpopulation, B-10, was reduced following IFNα treatment. In addition in diseased mice, B-10 versus B-2 ratios were reduced in IFN-treated B/W compared to the control PBS treated group. In all B/W the miR-15a was highly expressed in the B-10 subset and this increased with disease development, suggesting that miR-15a has a specific negative effect on the B-10 subpopulation. In conclusion, our data support the involvement of elevated miR-15a in autoimmune disease development in B/W mice and suggest that decreasing this microRNA might be beneficial in B/W mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.